Clinical question8 Sep 2020 09:58
The peak flow rate improved by 25l/min and this reached statistical significance.
Is this clinically significant - does it make a difference to patients and is it worth paying for.
Overall the interim seems to do what it intended to do - provide supportive data for covid - next step will be EUA in the States and inclusion in RECOVER. Disappointing that results require a further study for COPD - missed this flu season